A phase I, open-label, randomized, 2-part study to evaluate the bioequivalence of single oral doses of 2 different formulations of fenebrutinib and the effect of food and rabeprazole on the pharmacokinetics of fenebrutinib in healthy subjects
Latest Information Update: 27 Aug 2024
At a glance
- Drugs Fenebrutinib (Primary) ; Rabeprazole
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Roche
- 30 May 2024 Status changed from not yet recruiting to recruiting.
- 12 May 2024 New trial record